Table 2.
Results of the questions about hypersensitivity reactions and platinum- and taxane-based chemotherapy.
| Questions | Platinum n = 79 (n, %) |
Taxane n = 67 (n, %) |
|---|---|---|
| Gynecological cancers treated with platinum/taxane per year | ||
| >300 | 19 (24.1) | 15 (22.4) |
| 200–300 | 14 (17.7) | 13 (19.4) |
| 100–200 | 12 (15.2) | 12 (17.9) |
| 50–100 | 13 (16.5) | 12 (17.9) |
| 30–50 | 11 (13.9) | 11 (16.4) |
| 20–30 | 6 (7.6) | 2 (3.0) |
| 10–20 | 1 (1.3) | 1 (1.5) |
| <10 | 3 (3.8) | 1 (1.5) |
| HSRs to platinum/taxane per year | ||
| >50 | 4 (5.1) | 4 (6.0) |
| 30–50 | 9 (11.4) | 11 (16.4) |
| 20–30 | 5 (6.3) | 7 (10.4) |
| 10–20 | 22 (27.8) | 15 (22.4) |
| 5–10 | 18 (22.8) | 12 (17.9) |
| <5 | 20 (25.3) | 16 (23.9) |
| Other | 1 (1.3) | 2 (3.0) |
| HSRs to platinum/taxane CTCAE Grade 1–2 * | ||
| Premedication with antihistamines/steroids and new attempt with standard infusion | 67 (84.8) | 62 (92.5) |
| Suspension of the chemotherapy | 12 (15.2) | 11 (16.4) |
| Change the chemotherapy to, e.g., Oxaliplatin | 7 (8.9) | 11 (16.4) |
| Tolerance induction (stepwise increase of infusion rate of highly diluted platinum dilution) | 33 (41.8) | 14 (20.9) |
| Other | 3 (3.8) | 2 (2.9) |
| HSR to platinum/taxane CTCAE Grade 3–4 * | ||
| Premedication with antihistamines/steroids and new attempt with standard infusion | 25 (31.6) | 30 (44.8) |
| Suspension of the chemotherapy | 28 (35.4) | 25 (37.3) |
| Change the chemotherapy to, e.g., Oxaliplatin | 27 (34.1) | 30 (44.8) |
| Tolerance induction (stepwise increase of infusion rate of highly diluted platinum dilution) | 39 (49.4) | 28 (41.8) |
| Other | 0 (0.0) | 3 (4.5) |
| Performing tolerance induction of platinum/taxane | ||
| Yes †, at our clinic | 46 (58.2) | 37 (55.2) |
| No, but I referred the patient to another clinic | 13 (16.5) | 8 (11.9) |
| No | 20 (25.3) | 21 (31.3) |
| Other | 0 (0.0) | 1 (1.5) |
| † If yes, who performs the tolerance induction of platinum/taxane * | ||
| Allergologist | 22 (47.8) | 16 (43.2) |
| Medical oncologist | 32 (69.56) | 23 (62.12) |
| Specialist for internal medicine | 2 (4.3) | 0 (0.0) |
| Gynecologic oncologist | 12 (26.1) | 7 (18.9) |
| Other | 5 (10.8) | 4 (10.8) |
| How many times can you continue the chemotherapy after tolerance induction of platinum/taxane | ||
| every time | 15 (19.0) | 11 (16.4) |
| >50% | 38 (48.1) | 28 (41.8) |
| <50% | 18 (22.8) | 9 (13.4) |
| never | 8 (10.1) | 13 (19.4) |
| Other | 0 (0.0) | 6 (9.0) |
| Experience of a critical incident event in the course of the tolerance induction of platinum/taxane | ||
| Yes §, more than once | 20 (25.3) | 17 (25.4) |
| Yes §, once | 16 (20.3) | 12 (17.9) |
| No | 43 (54.4) | 35 (52.2) |
| Other (please specify) | 0 (0.0) | 3 (4.5) |
| § If yes, the reason(s) * | ||
| HSR to platinum/taxane CTCAE Grade 1–2 | 17 (47.2) | 10 (34.5) |
| HSR to platinum/taxane CTCAE Grade 3–4 | 24 (66.7) | 18 (62.1) |
| Death | 2 (5.6) | 1 (3.4) |
| Patient not informed about the risks of tolerance induction | 2 (5.6) | 1 (3.4) |
| Other | 4 (11.1) | 2 (6.9) |
* Multiple answers can be selected. † Link the answer to the follow-up question. § Link the answers to the follow-up question. n = Number, HSR = Hypersensitivity reaction, CTCAE = Common Terminology for Adverse Events.